Reportedly, the inflammatory environment in CKD induces the elevation of hepcidin, which may in turn require a higher dose of ESA therapy or result in hypo-responsiveness to ESA (Zheng et al., 2023). This evidence concerns the gene HAMP and chronic kidney disease.